MedPath

National Heart, Lung, and Blood Institute

National Heart, Lung, and Blood Institute logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

Phase 1
Active, not recruiting
Conditions
Sickle Cell Disease
Hemolytic Anemia
Interventions
First Posted Date
2020-11-02
Last Posted Date
2025-05-11
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
15
Registration Number
NCT04610866
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)

Completed
Conditions
Cardiomyopathy
Obstructive Hypertrophic Cardiomyopathy
First Posted Date
2020-10-27
Last Posted Date
2022-06-01
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
325
Registration Number
NCT04603521
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Fostamatinib for Hospitalized Adults With COVID-19

Phase 2
Completed
Conditions
Coronavirus Disease 2019
Interventions
Drug: Placebo
First Posted Date
2020-10-08
Last Posted Date
2022-03-02
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
59
Registration Number
NCT04579393
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇺🇸

INOVA Health Systems, Falls Church, Virginia, United States

COV2Base-A Rare Disease by COVID Study

Completed
Conditions
Chronic Health Conditions
Older Age is Associated With Increased Pathogenicity
First Posted Date
2020-09-25
Last Posted Date
2023-01-20
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
1748
Registration Number
NCT04564274
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

Phase 2
Completed
Conditions
Sickle Cell Disease
Interventions
Drug: Placebo
First Posted Date
2020-08-17
Last Posted Date
2024-01-02
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
46
Registration Number
NCT04514510
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

Early Phase 1
Completed
Conditions
Sickle Cell Disease
Sickle Cell Anemia
Interventions
First Posted Date
2020-07-20
Last Posted Date
2024-02-13
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
22
Registration Number
NCT04476277
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors

Conditions
Hematologic Diseases
Wide Spectrum of Diseases
First Posted Date
2020-06-30
Last Posted Date
2025-05-20
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
10000
Registration Number
NCT04450927
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7 Abnormalities After Immunosuppressive Therapy

Completed
Conditions
Severe Aplastic Anemia
First Posted Date
2020-06-18
Last Posted Date
2022-09-29
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
38
Registration Number
NCT04436367
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy

Completed
Conditions
Severe Aplastic Anemia
First Posted Date
2020-06-18
Last Posted Date
2023-03-16
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
173
Registration Number
NCT04436380
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

Completed
Conditions
Hypercoagulable State
Sickle Cell Disease
Sickle Cell Trait
Venous Thrombosis
Venous Thromboembolism
First Posted Date
2020-04-16
Last Posted Date
2025-04-24
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
119
Registration Number
NCT04349189
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath